The Effect of Vitamin D3 Supplementation on Advanced Glycation End Products, (AGEs) And Soluble Receptor, (sRAGE) in African Americans and Hispanics with Type 2 Diabetes and Vitamin D Insufficiency/Deficiency
Doctor of Philosophy (PhD)
Dietetics and Nutrition
First Advisor's Name
Fatma G. Huffman
First Advisor's Committee Title
Second Advisor's Name
Juan Liuzzi, PhD
Second Advisor's Committee Title
Third Advisor's Name
Third Advisor's Committee Title
Fourth Advisor's Name
Fourth Advisor's Committee Title
Advanced Glycation End Products, Type 2 diabetes, soluble receptor for Advanced Glycation End Products, vitamin D, African Americans, Hispanics
Date of Defense
There is a high burden of diabetes and its related complications globally. Advanced Glycation End Products (AGEs) and their receptors have been implicated in complications and mortality related to type 2 diabetes (T2D). Vitamin D deficiency, prevalent in persons with T2D, increases oxidative stress and inflammation that promotes the formation of AGEs.
This study assessed the relationship between sRAGE and AGEs and risk of cardiovascular diseases (CVD) and the effect of vitamin D3 supplementation on levels of AGEs and soluble receptor (sRAGE) in adults with hypovitaminosis D. African Americans and Hispanics (n=64) were recruited in Miami and were supplemented with either 4000 IU (n=41) or 6000 IU (n=23) of vitamin D3. AGEs and sRAGE were assessed using commercially available kits (Biotang Inc/TSZ Elisa, Waltham, MA, USA).
Cross-sectional results showed a negative and significant association between AGEs and high-density lipoprotein cholesterol (HDL-C) (B= −0.551, p= 0.029). The relationship between AGEs and HDL-C remained after adjusting for covariates (p=0.036). sRAGE was significantly associated with systolic blood pressure (SBP) (p= 0.029) and diastolic blood pressure (DBP) (p= 0.050). Results lost significance when association between sRAGE and DBP and SBP were adjusted for covariates such as age, body mass index (BMI), smoking, alcohol intake and use of medication. AGEs significantly increased at 3 months compared to baseline (p= 0.022). Compared to baseline, the mean level of AGEs decreased at 6 months of supplementation across all groups (Mean Difference= 9.81 ng/ml, p=0.003), 6000 IU group (Mean difference= 9.84 ng/ml, p=0.076) and 4000 IU group (Mean Difference= 9.79 ng/ml, p=0.020). Additionally, the mean serum levels of AGEs were significantly higher at 3 months compared to 6 months among study participants (Mean Difference= 18.71 ng/ml, p
AGEs and sRAGE are related to markers of CVD risk such as HDL-C, SBP and DBP in our study population. Higher serum levels of 25hydroxy vitamin D was associated with high levels of sRAGE. Supplementation of this minority population with vitamin D for six months may delay the accumulation of AGEs and complications of T2D.
Owusu, Justina Serwaah, "The Effect of Vitamin D3 Supplementation on Advanced Glycation End Products, (AGEs) And Soluble Receptor, (sRAGE) in African Americans and Hispanics with Type 2 Diabetes and Vitamin D Insufficiency/Deficiency" (2020). FIU Electronic Theses and Dissertations. 4401.
Human and Clinical Nutrition Commons, Molecular, Genetic, and Biochemical Nutrition Commons
In Copyright. URI: http://rightsstatements.org/vocab/InC/1.0/
This Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).